GTC Biotherapeutics Inc. of Framingham has struck a license agreement with a firm that will attempt to get sales authorizations for GTC’s products in three South American countries.
Under the registration license agreement, Bio Sidus, a biotech firm based in Buenos Aires, Argentina, will “perform all necessary actions to obtain sales authorizations for GTC’s lead product, ATryn, in Argentina, Uruguay and Paraguay.”
The company said it expects approval in Argentina in “no less than 6 months” once applications are filed.
GTC said it expects to forge a product license agreement with Bio Sidus separately.
ATryn is an anti-clotting drug based on a protein developed by GTC in the milk of genetically modified goats.
